The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
Status:
Terminated
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran
for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin
resistant (obese and T2DM) subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Nicolas Musi The University of Texas Health Science Center at San Antonio